Companies › BioLab Holdings
4 active drug programs in 4 registered trials: 4 Phase 4; Metabolic and endocrine; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Membrane Wrap-Hydro™ Human placental membrane product | – | Phase 4 | Diabetic Foot | Jul 2027 |
| Membrane Wrap-Lite™ Human placental membrane product | – | Phase 4 | Diabetic Foot | Jul 2027 |
| Membrane Wrap™ Human placental membrane product | – | Phase 4 | Diabetic Foot | Jul 2027 |
| Tri-Membrane Wrap™ Human placental membrane product | – | Phase 4 | Diabetic Foot | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07089602 | Tri-Membrane Wrap™ | Phase 4 | Diabetic Foot | Metabolic and endocrine | Jul 2027 |
| NCT07089602 | Membrane Wrap™ | Phase 4 | Diabetic Foot | Metabolic and endocrine | Jul 2027 |
| NCT07089602 | Membrane Wrap-Lite™ | Phase 4 | Diabetic Foot | Metabolic and endocrine | Jul 2027 |
| NCT07089602 | Membrane Wrap-Hydro™ | Phase 4 | Diabetic Foot | Metabolic and endocrine | Jul 2027 |
No annotated target.
–
Yong Zhao, MD, PhD Applied Biologics Spur Therapeutics iECURE Sequence LifeScience
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.